A Cannabis Drug Just Beat Opioids in a Clinical Trial. Here’s What That Means.

For the first time in modern medicine, a cannabis-derived pharmaceutical has received regulatory approval in Europe — and it didn’t just prove effective. It outperformed opioids.

On June 9, 2026, VERTANICAL, a biopharmaceutical company headquartered in Munich, Germany, announced that its drug Exilby® (VER-01) received marketing authorization in Germany for the treatment of chronic low back pain with a neuropathic component. Austria followed. This marks the first European marketing authorization ever granted for a cannabis-based prescription medicine targeting chronic pain.

What Is Exilby — and What Makes It Different?

Exilby is not a CBD oil. It is not a dispensary product. It is a precisely standardized, pharmaceutical-grade full-spectrum extract derived from a proprietary Cannabis sativa strain called DKJ127 L., developed specifically for chronic pain treatment. Every batch is analyzed using chromatographic and spectrometric methods to ensure an exact phytochemical profile — a level of consistency that distinguishes it fundamentally from other cannabis products on the market.

The company is explicit: findings from Exilby cannot be extrapolated to other cannabis extracts or products.

What the Trials Showed

Two pivotal Phase 3 randomized controlled trials — involving more than 1,200 patients — demonstrated significant pain reduction, a favorable tolerability profile, and no evidence of dependence.

In a direct head-to-head Phase 3 comparator study against opioids, Exilby delivered superior pain reduction and better gastrointestinal tolerability. For patients who have long faced a brutal trade-off between pain relief and addiction risk, this data is significant.

For decades, patients with chronic pain have too often been forced to choose between insufficient relief and unacceptable risk. The German marketing authorization of Exilby shows that a different path is possible.
– Dr. Clemens Fischer, CEO of FUTRUE Group and Founder of VERTANICAL

The Opioid Crisis Context

More than one billion people worldwide live with chronic pain, including more than 60 million Americans. Despite the scale of this problem, meaningful innovation in pain treatment has stagnated for decades. Opioids remain central to pain management — despite well-documented risks of dependence, abuse, and side effects that can be as debilitating as the pain itself.

Exilby enters this landscape as a credible, evidence-based alternative. Not a wellness product. Not an anecdote. A drug with Phase 3 data.

What About the United States?

Exilby is not yet FDA-approved. However, the FDA has granted it Breakthrough Therapy Designation — a recognition that the drug has potential to substantially improve treatment compared to available therapy. VERTANICAL has initiated a pivotal U.S. Phase 3 trial, with a first data read-out anticipated in 2027 and a New Drug Application planned for 2028, subject to positive results.

The Bottom Line

This is not a story about cannabis legalization. It is a story about what happens when cannabis science is applied with pharmaceutical rigor. Exilby is a landmark drug — the first to demonstrate, in a head-to-head trial, that a cannabis-derived medicine can outperform opioids in chronic pain. Its approval in Europe, and its path toward FDA review, represents a genuine inflection point for both the cannabis industry and pain medicine.